HRP950532B1 - Apolipoprotein-b synthesis inhibitors - Google Patents

Apolipoprotein-b synthesis inhibitors

Info

Publication number
HRP950532B1
HRP950532B1 HR950532A HRP950532A HRP950532B1 HR P950532 B1 HRP950532 B1 HR P950532B1 HR 950532 A HR950532 A HR 950532A HR P950532 A HRP950532 A HR P950532A HR P950532 B1 HRP950532 B1 HR P950532B1
Authority
HR
Croatia
Prior art keywords
apolipoprotein
synthesis inhibitors
inhibitors
synthesis
Prior art date
Application number
HR950532A
Other languages
English (en)
Inventor
Jan Heeres
Leo Jacobus Jozef Backx
Robert Jozef Maria Handrickx
Luc Alfons Leo Van Der Eycken
Didier Robert Guy G Courcelles
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/455,304 external-priority patent/US5521186A/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP950532A2 publication Critical patent/HRP950532A2/hr
Publication of HRP950532B1 publication Critical patent/HRP950532B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR950532A 1994-10-27 1995-10-27 Apolipoprotein-b synthesis inhibitors HRP950532B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203120 1994-10-27
US08/455,304 US5521186A (en) 1994-10-27 1995-05-31 Apolipoprotein-β synthesis inhibitors

Publications (2)

Publication Number Publication Date
HRP950532A2 HRP950532A2 (en) 1997-08-31
HRP950532B1 true HRP950532B1 (en) 2001-06-30

Family

ID=26136684

Family Applications (1)

Application Number Title Priority Date Filing Date
HR950532A HRP950532B1 (en) 1994-10-27 1995-10-27 Apolipoprotein-b synthesis inhibitors

Country Status (30)

Country Link
US (1) US5929075A (bg)
EP (1) EP0788496B1 (bg)
JP (1) JP3025907B2 (bg)
KR (1) KR100227231B1 (bg)
CN (1) CN1068000C (bg)
AP (1) AP779A (bg)
AT (1) ATE198889T1 (bg)
AU (1) AU697744C (bg)
BG (1) BG63694B1 (bg)
BR (1) BR9509436A (bg)
CA (1) CA2203274C (bg)
CY (1) CY2256B1 (bg)
CZ (1) CZ286476B6 (bg)
DE (3) DE122007000005I1 (bg)
DK (1) DK0788496T3 (bg)
ES (1) ES2155535T3 (bg)
FI (1) FI119548B (bg)
GR (1) GR3035519T3 (bg)
HR (1) HRP950532B1 (bg)
HU (1) HU219862B (bg)
IL (1) IL115771A (bg)
LU (1) LU91306I2 (bg)
NO (1) NO311937B1 (bg)
NZ (1) NZ295353A (bg)
OA (1) OA10479A (bg)
PT (1) PT788496E (bg)
RO (1) RO118715B1 (bg)
SK (1) SK281908B6 (bg)
TR (1) TR199501295A2 (bg)
WO (1) WO1996013499A1 (bg)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216238T1 (de) * 1997-11-03 2002-05-15 Janssen Pharmaceutica Nv Arzneimittel enthaltend lipidsenkende verbindungen
CN1308523A (zh) * 1998-04-27 2001-08-15 詹森药业有限公司 含有用降脂剂和聚合物包衣的丸芯的微丸
EP1140917B1 (en) 1998-12-22 2003-03-26 Janssen Pharmaceutica N.V. S-oxide lipid lowering compounds
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US20050132022A1 (en) * 2003-12-12 2005-06-16 International Business Machines Corporation Computer system with LAN-based I/O
US20080234291A1 (en) * 2004-01-21 2008-09-25 Marc Karel Jozef Francois Mitratapide Oral Solution
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20080280922A1 (en) * 2004-04-09 2008-11-13 Marc Alois Celine Maria Engelen Intermittent Dosing Regimen For Overweight and Obese Subjects
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
JP2008542255A (ja) * 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
JP2009503050A (ja) * 2005-08-04 2009-01-29 ファイザー・リミテッド ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8138188B2 (en) * 2006-02-23 2012-03-20 Pfizer Inc. Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
CA2669311C (en) 2006-11-13 2011-09-20 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
JP5350367B2 (ja) 2007-05-25 2013-11-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （２ｓ−シス）−２−（ブロモメチル）−２−（４−クロロフェニル）−１，３−ジオキソラン−４−メタノールメタンスルホネート（エステル）の改良された合成
KR101280786B1 (ko) * 2008-08-06 2013-07-05 화이자 리미티드 멜라노코르틴 4 작용제로서 다이아제핀 및 다이아조칸 화합물
CA2798002C (en) * 2010-05-19 2019-12-03 Sandoz Ag Process for the preparation of chiral triazolones
MX2020009228A (es) 2018-03-08 2021-01-08 Incyte Corp Compuestos diolicos de aminopirazina como inhibidores de fosfoinositida 3-cinasas-gamma.
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313953A (en) * 1978-06-23 1982-02-02 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4619931A (en) * 1983-02-28 1986-10-28 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (en) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
NZ223799A (en) * 1987-03-25 1989-12-21 Janssen Pharmaceutica Nv Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions
CA1331757C (en) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
AU6359594A (en) * 1993-03-04 1994-09-26 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors

Also Published As

Publication number Publication date
CY2256B1 (en) 2003-07-04
PT788496E (pt) 2001-07-31
DE122007000005I2 (de) 2008-04-24
FI971784A (fi) 1997-04-25
ES2155535T3 (es) 2001-05-16
US5929075A (en) 1999-07-27
DK0788496T3 (da) 2001-06-18
OA10479A (en) 2002-04-09
HU219862B (hu) 2001-08-28
DE69519995D1 (en) 2001-03-01
GR3035519T3 (en) 2001-06-29
ATE198889T1 (de) 2001-02-15
CZ119897A3 (cs) 1998-03-18
AU697744C (en) 2002-08-22
RO118715B1 (ro) 2003-09-30
FI119548B (fi) 2008-12-31
TR199501295A2 (tr) 1996-06-21
HRP950532A2 (en) 1997-08-31
LU91306I2 (fr) 2007-03-19
BG63694B1 (bg) 2002-09-30
EP0788496B1 (en) 2001-01-24
MX9703074A (es) 1997-07-31
SK50797A3 (en) 1998-04-08
EP0788496A1 (en) 1997-08-13
CN1161695A (zh) 1997-10-08
NZ295353A (en) 1998-08-26
WO1996013499A1 (en) 1996-05-09
BR9509436A (pt) 1998-01-06
AP779A (en) 1999-11-03
BG101402A (bg) 1997-10-31
DE69519995T2 (de) 2001-08-23
NO311937B1 (no) 2002-02-18
CZ286476B6 (en) 2000-04-12
HUT77360A (hu) 1998-03-30
JPH09511759A (ja) 1997-11-25
CA2203274A1 (en) 1996-05-09
DE122007000005I1 (de) 2007-04-26
NO971895L (no) 1997-04-24
AU697744B2 (en) 1998-10-15
KR100227231B1 (ko) 1999-11-01
AU3868095A (en) 1996-05-23
AP9700968A0 (en) 1997-04-30
IL115771A (en) 2000-02-29
NO971895D0 (no) 1997-04-24
IL115771A0 (en) 1996-01-19
SK281908B6 (sk) 2001-09-11
JP3025907B2 (ja) 2000-03-27
CA2203274C (en) 2002-02-19
CN1068000C (zh) 2001-07-04
FI971784A0 (fi) 1997-04-25

Similar Documents

Publication Publication Date Title
CY2256B1 (en) Apolipoprotein-b synthesis inhibitors
PL321759A1 (en) Novel thrombosin inhibitors
EP0835109A4 (en) PYRIDINONE-BASED THROMBIN INHIBITORS
ZA964895B (en) Benzamide derivatives
GB9511935D0 (en) Novel compound
ZA959084B (en) Apolipoprotein-b synthesis inhibitors
HU9503783D0 (en) Squvalen syntetase inhibitors
DE69523450D1 (en) Inhibitor
GB9413710D0 (en) Chiral synthesis
IL112244A0 (en) Novel inhibitor
GB9522007D0 (en) New compound
EP0747449A4 (en) BISAZO CONNECTION
ZA9610588B (en) Diamond synthesis
GB9504366D0 (en) Benzamide derivatives
GB9504868D0 (en) Benzamide derivatives
ZA981321B (en) Novel use of azoles
ZA962033B (en) New compound
GB9508745D0 (en) New compound
GB9515162D0 (en) New compound
GB9508826D0 (en) New Compound
GB9512972D0 (en) New compound
GB9524266D0 (en) New compound
GB9525105D0 (en) New compound
GB9516647D0 (en) New compound
GB9507254D0 (en) New compound

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20111022

Year of fee payment: 17

PPPP Transfer of rights

Owner name: ELANCO ANIMAL HEALTH IRELAND LIMITED, IE

PBON Lapse due to non-payment of renewal fee

Effective date: 20121028